Table 2. Nine ATL cases and one HTLV-1 carrier among allo-HSCT cases.
| Case | Age | Sex | Subtype | Chemo-therapy | Disease status |
Allo-HSCT (Source) |
Allo-HSCT (Conditioning) |
GVHD prophylaxis |
Acute GVHD |
Survival |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | F | Lymphoma | CHOP (1) +Mog (8) |
SD | Unrelated HLA full matched BM | TBI/CY | CSP+sMTX | Grade 2 skin | 355 days (dead) |
| 2 | 46 | F | acute | VCAP- VMPV-ECP (1)+Mog (4) |
CR | Unrelated HLA full matched BM | TBI/CY | FK+sMTX | Grade 2 skin | 295 days (alive) |
| 3 | 54 | M | acute | VCAP- VMPV-ECP (1)+Mog (8) |
CR | Unrelated HLA full matched BM | TBI/CY | FK+sMTX | Grade 2 skin | 546 days (alive) |
| 4 | 49 | F | Lymphoma | CHOP-VMMV | CR | CB | TBI/CY | CSP+sMTX | - | 138 days (dead, relapse) |
| 5 | 42 | M | Lymphoma | CHOP-VMMV | CR | CB | TBI/CY | CSP+sMTX | - | 135 days (dead, relapse) |
| 6 | 61 | F | acute | CHOP-VMMV | PR | CB | BU/FLU/TBI | CSP+sMTX | - | 28 days (dead, relapse) |
| 7 | 44 | F | acute | VCAP- VMPV-ECP |
CR | Unrelated HLA full matched BM | TBI/CY | FK+sMTX | - | 1084 days (alive) |
| 8 | 56 | F | acute | VCAP- VMPV-ECP |
CR | Unrelated HLA full matched BM | TBI/CY | FK+sMTX | - | 1156 days (alive) |
| 9 | 41 | F | acute | VCAP- VMPV-ECP |
CR | Unrelated HLA full matched BM | TBI/CY | FK+sMTX | - | 122 days (dead) |
| 10 | 60 | M | HTLV-1 carrier AML | AZA | PR | UR-BMT | FLU/BU/TBI | FK+sMTX | - | 1080 days (alive) |
Abbreviations: F:female, M:male, allo-HSCT: allogeneic hematopoietic stem cell transplantation, CR: complete response, PR: partial response, TBI: total body irradiation, CY: cyclophosphamide, FLU: Fludarabine, BU: busulfan, CB: cord blood, BM: bone marrow